Answers are grounded in this paper and cite their sources.
= 0.001), their 1-year PFS rates were higher than the compared groups. Moreover, patients with higher baseline tumor burdens were found to have significantly increased CRS incidence and cytokine levels. In conclusion, the PET/CT metabolic parameters are closely related to OS, PFS, and CRS in R/R NHL patients treated with CAR-T cells. This study may pave the way for building a comprehensive assessment system of tumor burden using 18F-FDG PET/CT, which can optimize therapeutic and supportive approaches in CAR-T cell therapy.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: